Braizon Therapeutics, Inc.

Braizon Therapeutics, Inc. is a Japan-based biotech firm focused on pioneering drug delivery systems for central nervous system disorders, leveraging innovative technology to enhance the transport of therapeutic agents across the blood-brain barrier. Braizon Therapeutics was founded in 2015 in Tokyo, Japan. The company develops advanced drug delivery systems aimed at treating central nervous system disorders.

Mariko Tosu is the founder, while Philip Davy serves as the CEO. The company has successfully raised JPY 300 million in its Series B funding round in July 2021, bringing the total amount raised to JPY 300 million and achieving a current valuation of JPY 1,960. 14 million. Braizon has completed two funding deals so far, the latest being funded by Fast Track Initiative and the University of Tokyo Innovation Platform, reflecting ongoing investor confidence in its strategic direction.

Braizon Therapeutics specializes in innovative drug delivery systems aimed at addressing central nervous system (CNS) disorders through its proprietary technology that enables effective transport of therapeutic agents across the blood-brain barrier (BBB). The core product offerings include a Drug Delivery System Platform developed from collaborative research efforts by renowned engineering and medical professors. This platform enhances drug delivery efficiency for CNS diseases like Alzheimer's and Parkinson's, utilizing specialized nanoparticles such as micro-nanocapsules modified with ligands. The company primarily targets pharmaceutical, biotechnology, and academic partners, with a global reach across North America, Europe, and Asia.

Braizon Therapeutics generates revenue primarily through licensing agreements with pharmaceutical and biotechnology companies, as well as collaborations with academic institutions. These partnerships typically involve Braizon licensing its Drug Delivery System Platform to develop new therapies for specific CNS disorders, structured around upfront fees, milestone payments, and royalties based on future sales of developed drugs. While specific pricing details are not disclosed, the value of these collaborations is driven by the advanced capabilities of Braizon's drug delivery technology, with a strong focus on unmet medical needs in CNS disorders. In July 2021, Braizon Therapeutics Inc.

raised JPY 300 million of venture funding from returning investors Fast Track Initiative and University of Tokyo Innovation Platform. The rationale for this continued investment highlights the social importance of maintaining research connections and the steady progress of their R&D activities. Future growth plans include the design and launch of new products targeting CNS disorders, with specific timelines for these developments not disclosed. The company aims to expand its market presence in North America, Europe, and Asia, leveraging the recent funding to support these initiatives and enhance its drug delivery systems.